TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Oncology Biosimilars Market, Global Outlook and Forecast 2023-2029

Oncology Biosimilars Market, Global Outlook and Forecast 2023-2029

  • Category:Life Sciences
  • Published on : 07 May 2023
  • Pages :60
  • Formats:
  • Report Code:SMR-7681540
OfferClick for best price

Best Price: $2600

Oncology Biosimilars Market Size, Share 2023


Biosimilar is the identical copy of oncology biologics used for the treatment of cancer and officially approved for the treatment of cancer. These molecules are cost-effective, efficient, and have the same ability as biologics. These molecules are easy to manufacture as compared to biologics and can only be manufactured after patent expiry. Earlier there were various patented biologics available in the market but nowadays most of the patents have expired and few are on the verge of patent expiry. In the past few years, various biosimilars have been approved by FDA for the treatment of various types of cancer such as blood cancer, colorectal cancer, breast cancer, and others. In the near future, it is expected that a few more biosimilars will be introduced in the market thus supporting the growth of the market.

This report aims to provide a comprehensive presentation of the global market for Oncology Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Biosimilars. This report contains market size and forecasts of Oncology Biosimilars in global, including the following market information:

Global Oncology Biosimilars Market Revenue, 2018-2023, 2024-2029, ($ millions)

Global top five companies in 2022 (%)

The global Oncology Biosimilars market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.

Monoclonal Antibody Segment to Reach $ Million by 2029, with a % CAGR in next six years.

The global key manufacturers of Oncology Biosimilars include Celltrion, Biocon, Dr. Reddy?s Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva Pharmaceutical Industries Ltd and Apotex, etc. in 2022, the global top five players have a share approximately % in terms of revenue.

We surveyed the Oncology Biosimilars companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Oncology Biosimilars Market, by Type, 2018-2023, 2024-2029 ($ millions)

Global Oncology Biosimilars Market Segment Percentages, by Type, 2022 (%)

Monoclonal Antibody

Hematopoietic Agents

G-CSF

Others

Global Oncology Biosimilars Market, by Application, 2018-2023, 2024-2029 ($ millions)

Global Oncology Biosimilars Market Segment Percentages, by Application, 2022 (%)

Retail Pharmacies

Hospital Pharmacy

Online Pharmacy

Global Oncology Biosimilars Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)

Global Oncology Biosimilars Market Segment Percentages, By Region and Country, 2022 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Oncology Biosimilars revenues in global market, 2018-2023 (estimated), ($ millions)

Key companies Oncology Biosimilars revenues share in global market, 2022 (%)

Further, the report presents profiles of competitors in the market, key players include:

Celltrion

Biocon

Dr. Reddy?s Laboratories

STADA Arzneimittel AG

Intas Pharmaceuticals

Pfizer

Sandoz International

Teva Pharmaceutical Industries Ltd

Apotex

BIOCAD

Outline of Major Chapters:

Chapter 1: Introduces the definition of Oncology Biosimilars, market overview.

Chapter 2: Global Oncology Biosimilars market size in revenue.

Chapter 3: Detailed analysis of Oncology Biosimilars company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Oncology Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: The main points and conclusions of the report.

Report Attributes Report Details
Report Title Oncology Biosimilars Market, Global Outlook and Forecast 2023-2029
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2022
Forecast Year 2030
Number of Pages 60 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Introduction to Research & Analysis Reports
1.1 Oncology Biosimilars Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Oncology Biosimilars Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Oncology Biosimilars Overall Market Size
2.1 Global Oncology Biosimilars Market Size: 2022 VS 2029
2.2 Global Oncology Biosimilars Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Oncology Biosimilars Players in Global Market
3.2 Top Global Oncology Biosimilars Companies Ranked by Revenue
3.3 Global Oncology Biosimilars Revenue by Companies
3.4 Top 3 and Top 5 Oncology Biosimilars Companies in Global Market, by Revenue in 2022
3.5 Global Companies Oncology Biosimilars Product Type
3.6 Tier 1, Tier 2 and Tier 3 Oncology Biosimilars Players in Global Market
3.6.1 List of Global Tier 1 Oncology Biosimilars Companies
3.6.2 List of Global Tier 2 and Tier 3 Oncology Biosimilars Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Oncology Biosimilars Market Size Markets, 2022 & 2029
4.1.2 Monoclonal Antibody
4.1.3 Hematopoietic Agents
4.1.4 G-CSF
4.1.5 Others
4.2 By Type - Global Oncology Biosimilars Revenue & Forecasts
4.2.1 By Type - Global Oncology Biosimilars Revenue, 2018-2023
4.2.2 By Type - Global Oncology Biosimilars Revenue, 2024-2029
4.2.3 By Type - Global Oncology Biosimilars Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Oncology Biosimilars Market Size, 2022 & 2029
5.1.2 Retail Pharmacies
5.1.3 Hospital Pharmacy
5.1.4 Online Pharmacy
5.2 By Application - Global Oncology Biosimilars Revenue & Forecasts
5.2.1 By Application - Global Oncology Biosimilars Revenue, 2018-2023
5.2.2 By Application - Global Oncology Biosimilars Revenue, 2024-2029
5.2.3 By Application - Global Oncology Biosimilars Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Oncology Biosimilars Market Size, 2022 & 2029
6.2 By Region - Global Oncology Biosimilars Revenue & Forecasts
6.2.1 By Region - Global Oncology Biosimilars Revenue, 2018-2023
6.2.2 By Region - Global Oncology Biosimilars Revenue, 2024-2029
6.2.3 By Region - Global Oncology Biosimilars Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Oncology Biosimilars Revenue, 2018-2029
6.3.2 US Oncology Biosimilars Market Size, 2018-2029
6.3.3 Canada Oncology Biosimilars Market Size, 2018-2029
6.3.4 Mexico Oncology Biosimilars Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Oncology Biosimilars Revenue, 2018-2029
6.4.2 Germany Oncology Biosimilars Market Size, 2018-2029
6.4.3 France Oncology Biosimilars Market Size, 2018-2029
6.4.4 U.K. Oncology Biosimilars Market Size, 2018-2029
6.4.5 Italy Oncology Biosimilars Market Size, 2018-2029
6.4.6 Russia Oncology Biosimilars Market Size, 2018-2029
6.4.7 Nordic Countries Oncology Biosimilars Market Size, 2018-2029
6.4.8 Benelux Oncology Biosimilars Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Oncology Biosimilars Revenue, 2018-2029
6.5.2 China Oncology Biosimilars Market Size, 2018-2029
6.5.3 Japan Oncology Biosimilars Market Size, 2018-2029
6.5.4 South Korea Oncology Biosimilars Market Size, 2018-2029
6.5.5 Southeast Asia Oncology Biosimilars Market Size, 2018-2029
6.5.6 India Oncology Biosimilars Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Oncology Biosimilars Revenue, 2018-2029
6.6.2 Brazil Oncology Biosimilars Market Size, 2018-2029
6.6.3 Argentina Oncology Biosimilars Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Oncology Biosimilars Revenue, 2018-2029
6.7.2 Turkey Oncology Biosimilars Market Size, 2018-2029
6.7.3 Israel Oncology Biosimilars Market Size, 2018-2029
6.7.4 Saudi Arabia Oncology Biosimilars Market Size, 2018-2029
6.7.5 UAE Oncology Biosimilars Market Size, 2018-2029
7 Oncology Biosimilars Companies Profiles
7.1 Celltrion
7.1.1 Celltrion Company Summary
7.1.2 Celltrion Business Overview
7.1.3 Celltrion Oncology Biosimilars Major Product Offerings
7.1.4 Celltrion Oncology Biosimilars Revenue in Global Market (2018-2023)
7.1.5 Celltrion Key News & Latest Developments
7.2 Biocon
7.2.1 Biocon Company Summary
7.2.2 Biocon Business Overview
7.2.3 Biocon Oncology Biosimilars Major Product Offerings
7.2.4 Biocon Oncology Biosimilars Revenue in Global Market (2018-2023)
7.2.5 Biocon Key News & Latest Developments
7.3 Dr. Reddy?s Laboratories
7.3.1 Dr. Reddy?s Laboratories Company Summary
7.3.2 Dr. Reddy?s Laboratories Business Overview
7.3.3 Dr. Reddy?s Laboratories Oncology Biosimilars Major Product Offerings
7.3.4 Dr. Reddy?s Laboratories Oncology Biosimilars Revenue in Global Market (2018-2023)
7.3.5 Dr. Reddy?s Laboratories Key News & Latest Developments
7.4 STADA Arzneimittel AG
7.4.1 STADA Arzneimittel AG Company Summary
7.4.2 STADA Arzneimittel AG Business Overview
7.4.3 STADA Arzneimittel AG Oncology Biosimilars Major Product Offerings
7.4.4 STADA Arzneimittel AG Oncology Biosimilars Revenue in Global Market (2018-2023)
7.4.5 STADA Arzneimittel AG Key News & Latest Developments
7.5 Intas Pharmaceuticals
7.5.1 Intas Pharmaceuticals Company Summary
7.5.2 Intas Pharmaceuticals Business Overview
7.5.3 Intas Pharmaceuticals Oncology Biosimilars Major Product Offerings
7.5.4 Intas Pharmaceuticals Oncology Biosimilars Revenue in Global Market (2018-2023)
7.5.5 Intas Pharmaceuticals Key News & Latest Developments
7.6 Pfizer
7.6.1 Pfizer Company Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Oncology Biosimilars Major Product Offerings
7.6.4 Pfizer Oncology Biosimilars Revenue in Global Market (2018-2023)
7.6.5 Pfizer Key News & Latest Developments
7.7 Sandoz International
7.7.1 Sandoz International Company Summary
7.7.2 Sandoz International Business Overview
7.7.3 Sandoz International Oncology Biosimilars Major Product Offerings
7.7.4 Sandoz International Oncology Biosimilars Revenue in Global Market (2018-2023)
7.7.5 Sandoz International Key News & Latest Developments
7.8 Teva Pharmaceutical Industries Ltd
7.8.1 Teva Pharmaceutical Industries Ltd Company Summary
7.8.2 Teva Pharmaceutical Industries Ltd Business Overview
7.8.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Major Product Offerings
7.8.4 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Revenue in Global Market (2018-2023)
7.8.5 Teva Pharmaceutical Industries Ltd Key News & Latest Developments
7.9 Apotex
7.9.1 Apotex Company Summary
7.9.2 Apotex Business Overview
7.9.3 Apotex Oncology Biosimilars Major Product Offerings
7.9.4 Apotex Oncology Biosimilars Revenue in Global Market (2018-2023)
7.9.5 Apotex Key News & Latest Developments
7.10 BIOCAD
7.10.1 BIOCAD Company Summary
7.10.2 BIOCAD Business Overview
7.10.3 BIOCAD Oncology Biosimilars Major Product Offerings
7.10.4 BIOCAD Oncology Biosimilars Revenue in Global Market (2018-2023)
7.10.5 BIOCAD Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Oncology Biosimilars Market Opportunities & Trends in Global Market
Table 2. Oncology Biosimilars Market Drivers in Global Market
Table 3. Oncology Biosimilars Market Restraints in Global Market
Table 4. Key Players of Oncology Biosimilars in Global Market
Table 5. Top Oncology Biosimilars Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Oncology Biosimilars Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Oncology Biosimilars Revenue Share by Companies, 2018-2023
Table 8. Global Companies Oncology Biosimilars Product Type
Table 9. List of Global Tier 1 Oncology Biosimilars Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Oncology Biosimilars Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Oncology Biosimilars Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Oncology Biosimilars Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Oncology Biosimilars Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Oncology Biosimilars Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Oncology Biosimilars Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Oncology Biosimilars Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Oncology Biosimilars Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Oncology Biosimilars Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Oncology Biosimilars Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Oncology Biosimilars Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Oncology Biosimilars Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Oncology Biosimilars Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Oncology Biosimilars Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Oncology Biosimilars Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Oncology Biosimilars Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Oncology Biosimilars Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Oncology Biosimilars Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Oncology Biosimilars Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Oncology Biosimilars Revenue, (US$, Mn), 2024-2029
Table 30. Celltrion Company Summary
Table 31. Celltrion Oncology Biosimilars Product Offerings
Table 32. Celltrion Oncology Biosimilars Revenue (US$, Mn) & (2018-2023)
Table 33. Celltrion Key News & Latest Developments
Table 34. Biocon Company Summary
Table 35. Biocon Oncology Biosimilars Product Offerings
Table 36. Biocon Oncology Biosimilars Revenue (US$, Mn) & (2018-2023)
Table 37. Biocon Key News & Latest Developments
Table 38. Dr. Reddy?s Laboratories Company Summary
Table 39. Dr. Reddy?s Laboratories Oncology Biosimilars Product Offerings
Table 40. Dr. Reddy?s Laboratories Oncology Biosimilars Revenue (US$, Mn) & (2018-2023)
Table 41. Dr. Reddy?s Laboratories Key News & Latest Developments
Table 42. STADA Arzneimittel AG Company Summary
Table 43. STADA Arzneimittel AG Oncology Biosimilars Product Offerings
Table 44. STADA Arzneimittel AG Oncology Biosimilars Revenue (US$, Mn) & (2018-2023)
Table 45. STADA Arzneimittel AG Key News & Latest Developments
Table 46. Intas Pharmaceuticals Company Summary
Table 47. Intas Pharmaceuticals Oncology Biosimilars Product Offerings
Table 48. Intas Pharmaceuticals Oncology Biosimilars Revenue (US$, Mn) & (2018-2023)
Table 49. Intas Pharmaceuticals Key News & Latest Developments
Table 50. Pfizer Company Summary
Table 51. Pfizer Oncology Biosimilars Product Offerings
Table 52. Pfizer Oncology Biosimilars Revenue (US$, Mn) & (2018-2023)
Table 53. Pfizer Key News & Latest Developments
Table 54. Sandoz International Company Summary
Table 55. Sandoz International Oncology Biosimilars Product Offerings
Table 56. Sandoz International Oncology Biosimilars Revenue (US$, Mn) & (2018-2023)
Table 57. Sandoz International Key News & Latest Developments
Table 58. Teva Pharmaceutical Industries Ltd Company Summary
Table 59. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Offerings
Table 60. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Revenue (US$, Mn) & (2018-2023)
Table 61. Teva Pharmaceutical Industries Ltd Key News & Latest Developments
Table 62. Apotex Company Summary
Table 63. Apotex Oncology Biosimilars Product Offerings
Table 64. Apotex Oncology Biosimilars Revenue (US$, Mn) & (2018-2023)
Table 65. Apotex Key News & Latest Developments
Table 66. BIOCAD Company Summary
Table 67. BIOCAD Oncology Biosimilars Product Offerings
Table 68. BIOCAD Oncology Biosimilars Revenue (US$, Mn) & (2018-2023)
Table 69. BIOCAD Key News & Latest Developments
List of Figures
Figure 1. Oncology Biosimilars Segment by Type in 2022
Figure 2. Oncology Biosimilars Segment by Application in 2022
Figure 3. Global Oncology Biosimilars Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Oncology Biosimilars Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Oncology Biosimilars Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Oncology Biosimilars Revenue in 2022
Figure 8. By Type - Global Oncology Biosimilars Revenue Market Share, 2018-2029
Figure 9. By Application - Global Oncology Biosimilars Revenue Market Share, 2018-2029
Figure 10. By Type - Global Oncology Biosimilars Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Oncology Biosimilars Revenue Market Share, 2018-2029
Figure 12. By Application - Global Oncology Biosimilars Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Oncology Biosimilars Revenue Market Share, 2018-2029
Figure 14. By Region - Global Oncology Biosimilars Revenue Market Share, 2018-2029
Figure 15. By Country - North America Oncology Biosimilars Revenue Market Share, 2018-2029
Figure 16. US Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Oncology Biosimilars Revenue Market Share, 2018-2029
Figure 20. Germany Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 21. France Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Oncology Biosimilars Revenue Market Share, 2018-2029
Figure 28. China Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 32. India Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Oncology Biosimilars Revenue Market Share, 2018-2029
Figure 34. Brazil Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Oncology Biosimilars Revenue Market Share, 2018-2029
Figure 37. Turkey Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Oncology Biosimilars Revenue, (US$, Mn), 2018-2029
Figure 41. Celltrion Oncology Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Biocon Oncology Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Dr. Reddy?s Laboratories Oncology Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. STADA Arzneimittel AG Oncology Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Intas Pharmaceuticals Oncology Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Pfizer Oncology Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Sandoz International Oncology Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Apotex Oncology Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. BIOCAD Oncology Biosimilars Revenue Year Over Year Growth (US$, Mn) & (2018-2023)

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount